Health News

The first clinical trials on a new investigational drug being developed to treat infections caused by Hepatitis C virus have been successfully completed.

Read more

Filed under: Pharmacy News
Tags: Drug, Hepatitis, Pharmacy

Related posts

• Vertex submits NDA for telaprevir for treating hepatitis C (0)
  Vertex Pharmaceuticals Incorporated announced today that it has completed the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for telaprevir, Vertex's investigational treatment for people with hepatitis C. Read more [tags] Pharmacy News [/tags]
  
  
• Vertex receives FDA approval for INCIVEK to treat hepatitis C (0)
  Vertex Pharmaceuticals Incorporated today announced that the U.S. Food and Drug Administration (FDA) has approved INCIVEK™ (telaprevir) tablets for a broad group of people with genotype 1 chronic hepatitis C with compensated liver disease (some level of damage to the liver but the liver still functions), including cirrhosis (scarring of the liver). Read more [tags] Pharmacy News [...]
  
  
• Vertex Incivek receives FDA approval for treatment of chronic hepatitis C (0)
  The U.S. Food and Drug Administration today approved Incivek treat certain adults with chronic hepatitis C infection. Incivek is used for patients who have either not received interferon-based drug therapy for their infection or who have not responded adequately to prior therapies. Incivek is approved for use with interferon therapy made up of peginterferon alfa [...]
  
  
• Two new hepatitis C drugs effectively improve cure rates of African Americans (0)
  Two new drugs just approved by the Food and Drug Administration to treat hepatitis C genotype 1 significantly improved the cure rates of patients. One of the drugs was extremely effective in treating African Americans. Read more [tags] Pharmacy News [/tags]
  
  
• Treatment for HBV infection with entecavir followed by lamivudine results in virologic rebound (0)
  A two-year trial of entecavir followed by lamivudine (LAM) in patients with chronic hepatitis B virus (HBV) infection resulted in a virologic rebound rate of 24% and 12% drug-resistance rate. Patients who continued on entecavir therapy throughout the study period had undetectable HBV DNA at the two-year endpoint. Details of this trial are published in [...]